PMID- 24667260
OWN - NLM
STAT- MEDLINE
DCOM- 20150129
LR  - 20211021
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 17
IP  - 3
DP  - 2014 Mar
TI  - [The research of clinical pathological features of ALK positive lung cancer in 
      525 patients and the discussion of detection methods].
PG  - 226-32
LID - 10.3779/j.issn.1009-3419.2014.03.08 [doi]
AB  - BACKGROUND: The fusion (rearrangement) of anaplastic lymphoma kinase (ALK) gene 
      has been identified as an import factor to the tumorigenesis and development of 
      lung cancer. ALK tyrosine kinase inhibitors (ALK-TKIs) have been proved to have 
      good effects to ALK positive lung cancers. The increasement of the relevance 
      ratio of ALK will be very important to patients. The aim of this study is to 
      investigate the clinical pathological features of ALK positive lung cancer, and 
      the roles of immunohistochemistry (IHC) and fluorescence in situ hybridization 
      (FISH) in screening and confirming the ALK positive cases in the testing flow of 
      ALK. METHODS: IHC analysis of ALK in tumor specimens was performed on 525 lung 
      cancer patients. 34 cases among them were confirmed by FISH. RESULTS: The 
      positive incidence of ALK by IHC was 5.14% (27/525). The ALK positive patients 
      were significantly younger than ALK negative patients (P<0.05), and femal was 
      predominant (P<0.05). The proportion of solid predominant adenocarcinoma was 
      significantly higher in ALK positive patients (P<0.05). While acinar and lepidic 
      predominant adenocarcinoma were significantly lower in ALK positive patients 
      (P<0.05). FISH was applied in 34 cases. The coincidence rate was increased with 
      the increasement of positive intensity of IHC staining. All the IHC positive 
      cases with or without EGFR mutation must be confirmed by FISH. CONCLUSIONS: IHC 
      is a reliable detection method to screening the ALK in lung cancer, and then 
      enhance the relevance ration. To make a definite diagnosis of ALK positive lung 
      cancer, FISH is a significant detection method.
FAU - Zhu, Xiang
AU  - Zhu X
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Li, Hongwei
AU  - Li H
AD  - Department of Pathology, Beijing Chui Yang Liu Hospital, Beijing 100022, China.
FAU - Cao, Baoshan
AU  - Cao B
AD  - Department of Oncology and Radiation Sickness, Cancer Center, Peking University 
      Third Hospital, Beijing 100191, China.
FAU - Liu, Chen
AU  - Liu C
AD  - Department of Radiology, Peking University Third Hospital, Beijing 100191, China.
FAU - Liang, Li
AU  - Liang L
AD  - Department of Oncology and Radiation Sickness, Cancer Center, Peking University 
      Third Hospital, Beijing 100191, China.
FAU - Wang, Yuxiang
AU  - Wang Y
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - You, Jiangfeng
AU  - You J
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Gao, Fei
AU  - Gao F
AD  - Gene Tech (Shanghai) Company Limited, Beijing 100053, China.
FAU - Ma, Xiaolong
AU  - Ma X
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Wang, Hua
AU  - Wang H
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Chen, Jian
AU  - Chen J
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Pathology, Peking University, Health Science Center/Peking 
      University Third Hospital, Beijing 100191, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - ErbB Receptors/genetics/metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/diagnosis/*enzymology/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/genetics/*metabolism
PMC - PMC6019375
EDAT- 2014/03/29 06:00
MHDA- 2015/01/30 06:00
PMCR- 2014/03/20
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/01/30 06:00 [medline]
PHST- 2014/03/20 00:00 [pmc-release]
AID - zgfazz-17-3-226 [pii]
AID - 10.3779/j.issn.1009-3419.2014.03.08 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2014 Mar;17(3):226-32. doi: 
      10.3779/j.issn.1009-3419.2014.03.08.